Filing Flows

Filing Flows › Nektar Therapeutics (NKTR) › Who owns the stock

Who owns Nektar Therapeutics (NKTR) stock

230 funds reported Nektar Therapeutics (NKTR) shares in their latest 13F filings, worth $2.5B in all. The largest holder is FMR LLC ($354M). Last quarter 159 funds added to their stakes and 78 cut them.

Largest holders of NKTR (13F)Largest holders of NKTR (13F)FMR LLC$354MBlackRock$205MTwo Seas Capital LP$203MBVF$167MVanguard Capital Management LLC$104MTwo Sigma Investments, LP$83.9MVestal Point Capital, LP$69.8MMorgan Stanley$65.4MState Street$63.5MGeode Capital Management, LLC$61.5M

Largest holders (13F)

FundSharesValueChangeQuarter
FMR LLC5,067,920$354Mincrease2026-06-30
BlackRock2,941,851$205Mincrease2026-06-30
Two Seas Capital LP3,345,978$203Mincrease2026-09-30
BVF2,391,075$167Mdecrease2026-06-30
Vanguard Capital Management LLC1,496,849$104Mincrease2026-06-30
Two Sigma Investments, LP1,202,004$83.9Mincrease2026-06-30
Vestal Point Capital, LP1,000,000$69.8Mincrease2026-06-30
Morgan Stanley936,560$65.4Mincrease2026-06-30
State Street909,679$63.5Mincrease2026-06-30
Geode Capital Management, LLC881,306$61.5Mincrease2026-06-30
Prosight Management, LP810,000$56.5Mincrease2026-06-30
Armistice Capital, LLC724,000$50.5Mincrease2026-06-30
Vanguard Group1,027,089$43.4Mincrease2025-12-31
Gilder Gagnon Howe & Co LLC600,873$41.9Mincrease2026-06-30
Millennium Management LLC478,120$33.4Mincrease2026-06-30

Nektar Therapeutics' latest quarter

Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most NKTR stock?

By the latest 13F filings: FMR LLC ($354M); BlackRock ($205M); Two Seas Capital LP ($203M); BVF ($167M); Vanguard Capital Management LLC ($104M).

What is the short interest in NKTR?

6,997,725 shares were sold short at the 2026-10-15 settlement, 0.42% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.